Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.
This is a multicentric, observational and retrospective study of the use of lenalidomide in patients with relapsed or refractory mantle cell lymphoma that are included in the RRMCL spanish program.
The lenalidomide effectiveness and tolerability data will be retrospectely collected until the 30 of April 2018.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Carlos García Pérez
- Phone Number: 955 00 80 00
- Email: administracion.eecc.hvm.sspa@juntadeandalucia.es
Study Locations
-
-
-
Sevilla, Spain, 41009
- Recruiting
- Hospital Universitario Virgen Macarena
-
Contact:
- Carlos García Pérez
- Phone Number: 955 00 80 00
- Email: administracion.eecc.hvm.sspa@juntadeandalucia.es
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- ≥ 18 years old.
- Diagnosed with relapsed or refractory mantle cell lymphoma verified by a tissue biopsy.
- Treated with monotherapy or combination of lenalidomide.
- Not candidate for any of the therapeutic options approved until that date for this disease.
- Not candidate or unable to be included in any clinical trial due to availability or geographical difficulty.
- Registered in the RRMCL spanish program.
Exclusion Criteria:
- ECOG > 2.
- Patients with uncontrolled comorbidities.
- Blastoid variant.
- Central nervous system tumor infiltration.
- HIV, HBV and/or HCV active infection.
- Radiotherapy concomitant treatment or that have received radiotherapy in the previous 30 days to the beginning of the first cycle of lenalidomide.
- Diagnosed with other active solid tumor except for basal cell carcinoma skin cancer.
- Patients that haven´t completed at least one complete cycle of the treatment.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Mantle cell lymphoma treated with lenalidomide cohort
Patients diagnosed with mantle cell lymphoma treated with leanalidomide through the RRMCL spanish program.
|
Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Experience of real clinal practice lenalidomide use.
Time Frame: Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
|
Results of the the usage in real clinical practice of the lenalidomide monotherapy or combination treatment in patients with relapsed or refractory mantle cell lymphoma that aren´t candidate to other alternative treatments inside the RRMCL spanish program.
|
Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients that achieve objective response.
Time Frame: Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
|
The objective response will be measured in terms of complete response, not confirmed complete response and partial response according to the 2007 International Working Group criteria after the 6º treatment cycle.
|
Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
|
|
Duration of the response.
Time Frame: Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
|
Partial and complete response duration.
|
Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
|
|
Verify the disease free survival.
Time Frame: Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
|
The disease free survival is defined as the time that passes from the inclusion in the record until a control is done or takes place a relapse (local or distant).
|
Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
|
|
Verify the disease overall survival.
Time Frame: Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
|
The disease overall survival is defined as the time that passes from the inclusion in the record until a control is done or the patient´s death.
|
Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
|
|
Evaluate the incidence of treatment adverse events.
Time Frame: Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
|
Number and description of adverse effects due to the lenalidomide treatment.
|
Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Carlos García Pérez, Hospital Universitario Virgen Macarena
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, Mantle-Cell
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
Other Study ID Numbers
Other Study ID Numbers
- FIS-LEN-2018-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.